CTIS2022-501883-17-00招募中1 期
(21196) A multicenter, prospective, open-label study to evaluate the pharmacokinetics and safety of gadoquatrane in pediatric participants (from birth to <18 years) undergoing contrast-enhanced magnetic resonance imaging (CE-MRI) - 21196
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Bayer AG
- 入组人数
- 141
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Participants from birth to <18 years of age at the time of signing the informed consent form, Participants who have a clinical indication to undergo a CE-MRI for any clinical condition in any body region and who can undergo study procedures as per Investigator judgement, Participants can be male or female (according to their reproductive organs and functions assigned by chromosomal complement), Female contraception and barriers as well as pregnancy testing is required as appropriate for the age and sexual activity of pediatric participants and as required by local regulations, The legal guardian(s) is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, When applicable by law for a participant, a legal guardian must be available to help the study-site personnel ensure follow up, accompany the participant to the study site on each assessment day, and consistently and consecutively be available to provide information on the participant during the scheduled study visits
排除标准
- •Body weight <2500 g at screening and baseline, Participants who received or will receive any other contrast agent within 72 hours prior to gadoquatrane injection or up to 72 hours after gadoquatrane injection, Contraindications to the administration of GBCAs (depending on local product label), or history of adverse reaction to GBCAs, The medical condition and/or local allowance for maximum blood draw in the pediatric participant is not suitable for study procedures, including PK and safety blood draws, without compromising any expected clinical care/procedure need, Acute kidney injury (i.e., acute renal failure), Age-adjusted renal function is decreased (eGFR <80% of age adjusted normal renal function) as evaluated by the investigator based on a serum or plasma creatinine result obtained within 2 weeks prior to study intervention., Considered clinically unstable or has a concurrent/concomitant condition that may not allow participation for the full planned study period, in the judgement of the investigator, History of moderate to severe allergic-like reaction to any GBCA, Bronchial asthma which is considered unstable or had major therapeutical modification within last 4 weeks., Severe cardiovascular disease, except for cardiac or vascular magnetic resonance (MR), if considered clinically justified by the investigator, Planned or expected intervention (e.g., treatment or procedure) or change in treatment (e.g. start of chemotherapy) that may significantly affect study parameters (i.e. safety/AEs [e.g. confounding AEs or safety events due to surgery or chemotherapy], PK parameters) or would prevent the participant from performing study procedures, from the administration of gadoquatrane up to the 24 h ± 4 h follow-up
研究者
相似试验
招募中
不适用
A prospective, multicenter, open-label, observation study evaluating the efficacy and safety of edoxaban in patients with cancer-associated venous thromboembolismKCT0004697Yonsei University Health System, Severance Hospital300
进行中（未招募）
1 期
Calcinosis cutis in SSc patients treated with sodium thiosulfate assessed by biomarkers and imagingCalcinosis cutis in systemic sclerosisCTIS2023-510255-34-00Aarhus Universitetshospital75
进行中（未招募）
不适用
A prospective, multicentre, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third lineAdvanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 17.1Level: PTClassification code 10033158Term: Ovarian epithelial cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000491-14-ESAB Science56
招募中
1 期
This is a non-comparative study that aims to evaluate and confirm the effects of the Effimia® contraceptive pill on intermenstrual bleeding.Combined Oral Contraceptives (COC)MedDRA version: 20.0Level: SOCClassification code 10014698Term: Endocrine disordersSystem Organ Class: 10014698 - Endocrine disordersEUCTR2021-003027-15-ITITALFARMACO S.P.A.228
已完成
4 期
A study to evaluate the efficacy and safety of vestige spirulina capsules for the immunity in healthy patients.CTRI/2022/09/045585Vestige Marketing Pvt Ltd50